Literature DB >> 16418594

Characterization of neuronopathic Gaucher disease among ethnic Poles.

Anna Tylki-Szymañska1, Mehdi Keddache, Gregory A Grabowski.   

Abstract

PURPOSE: Gaucher disease is a common lysosomal storage disease that results from inherited mutations in the gene (GBA) encoding acid beta-glucosidase (GCase). Here, the clinical and molecular findings of the subacute neuronopathic variant are delineated among ethnic Poles.
METHODS: Longitudinal studies of visceral, bony, and central nervous system involvement are delineated clinically. Complete gene GBA sequencing was used to characterize the mutations and haplotypes in this population.
RESULTS: A greater frequency of subacute neuronopathic Gaucher disease (type 3) is present among ethnic Poles compared with other European countries. Two type 3 phenotypes were found: The first was an early-onset variant with massive visceral disease, progressive kyphoscoliosis, mild cognitive deficits, and survival for three or more decades. This variant resembles the "Norrbottnian" Swedish phenotype. The other variant had more severe progressive central nervous system disease, milder visceral involvement, and absence of kyphoscoliosis. Myoclonus was present in some patients. Neither variant had bone crises and/or pain as major components. The L444P/L444P genotype was most common, but on several different haplotype backgrounds. Other alleles encoded D409H, V305L, and E326K/A446P on various haplotypes.
CONCLUSIONS: These studies provide additional expansion of the type 3 genotypes with some commonalities with and differences from other reported variants. Also, such phenotypic expansion should be expected in the other variants of Gaucher disease as the spectrum of ethnic variation becomes more fully delineated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16418594     DOI: 10.1097/01.gim.0000196443.42899.25

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  10 in total

Review 1.  Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.

Authors:  Hagit N Baris; Ian J Cohen; Pramod K Mistry
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

Review 2.  A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease.

Authors:  E H Davies; R Surtees; C DeVile; I Schoon; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2007-09-16       Impact factor: 4.982

3.  Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry.

Authors:  Anna Tylki-Szymańska; Ashok Vellodi; Amal El-Beshlawy; J Alexander Cole; Edwin Kolodny
Journal:  J Inherit Metab Dis       Date:  2010-01-19       Impact factor: 4.982

4.  Management of neuronopathic Gaucher disease: revised recommendations.

Authors:  A Vellodi; A Tylki-Szymanska; E H Davies; E Kolodny; B Bembi; T Collin-Histed; E Mengel; A Erikson; R Schiffmann
Journal:  J Inherit Metab Dis       Date:  2009-08-05       Impact factor: 4.982

Review 5.  Gaucher disease: Basic and translational science needs for more complete therapy and management.

Authors:  Gregory A Grabowski; Armand H M Antommaria; Edwin H Kolodny; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2020-12-29       Impact factor: 4.797

6.  Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula.

Authors:  Pilar Giraldo; Pilar Alfonso; Pilar Irún; Laura Gort; Amparo Chabás; Lluïsa Vilageliu; Daniel Grinberg; Clara M Sá Miranda; Miguel Pocovi
Journal:  Orphanet J Rare Dis       Date:  2012-03-19       Impact factor: 4.123

Review 7.  Neurological effects of glucocerebrosidase gene mutations.

Authors:  S Mullin; D Hughes; A Mehta; A H V Schapira
Journal:  Eur J Neurol       Date:  2018-12-13       Impact factor: 6.089

8.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15

9.  The appearance of newly identified intraocular lesions in Gaucher disease type 3 despite long-term glucocerebrosidase replacement therapy.

Authors:  Nadia Sawicka-Gutaj; Maciej Machaczka; Izabela Kulińska-Niedziela; Jadwiga Bernardczyk-Meller; Paweł Gutaj; Jerzy Sowiński; Marek Ruchała
Journal:  Ups J Med Sci       Date:  2016-04-11       Impact factor: 2.384

10.  Gaucher disease in Syrian children: common mutations identification, and clinical futures.

Authors:  Diana Alasmar
Journal:  Ann Saudi Med       Date:  2015 Mar-Apr       Impact factor: 1.526

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.